Proton pump inhibitors affect the gut microbiome

Gut

Volumn 65, Issue 5, 2016, Pages 740-748

  Imhann, Floris ^a   Bonder, Marc Jan ^a   Vila, Arnau Vich ^a   Fu, Jingyuan ^a   Mujagic, Zlatan ^b   Vork, Lisa ^b   Tigchelaar, Ettje F ^a   Jankipersadsing, Soesma A ^a   Cenit, Maria Carmen ^a   Harmsen, Hermie J M ^a   Dijkstra, Gerard ^a   Franke, Lude ^a   Xavier, Ramnik J ^c   Jonkers, Daisy ^b   Wijmenga, Cisca ^a   Weersma, Rinse K ^a   Zhernakova, Alexandra ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR; RNA 16S;

ADULT; AGE DISTRIBUTION; ARTICLE; BACTERIUM IDENTIFICATION; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; DRUG USE; ENTEROCOCCUS; ESCHERICHIA COLI; FECES ANALYSIS; FEMALE; HUMAN; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SPECIES COMPOSITION; SPECIES DIVERSITY; STAPHYLOCOCCUS; STREPTOCOCCUS; TAXONOMIC IDENTIFICATION; DRUG EFFECTS;

ADULT; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS;

EID: 84954286591     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310376     Document Type: Article

References (37)

1. The Dutch Foundation for Pharmaceutical Statistics (SFK). Data and Facts on 2013. 2014.
2. Drugs.com. Top 100 sales in the United States in 2013. 2013.
3. Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2003;2:132-9.
4. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet 2006;367:2086-100.
5. McDonald EG, Milligan J, Frenette C, et al. Continuous proton pump inhibitor therapy and the associated risk of recurrent clostridium difficile infection. JAMA Intern Med 2015;175:784-91.
6. Kelly OB, Dillane C, Patchett SE, et al, The Inappropriate prescription of oral proton pump inhibitors in the hospital setting: a prospective cross-sectional study. Dig Dis Sci 2015;60:2280-6.
7. Bouwknegt M, Pelt W Van, Kubbinga ME, et al. Potential association between the recent increase in campylobacteriosis incidence in the Netherlands and proton-pump inhibitor use-an ecological study. Eurosurveillance 2014;19:1-6.
8. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047-56.
9. Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: a Meta-Analysis. Am J Gastroenterol 2012;107:1001-10.
10. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol. 2013;13:790-801.
11. Kamada N, Chen GY, Inohara N, et al. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol 2013;14:685-90.
12. Britton RA., Young VB. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 2014;146:1547-53.
13. Buffie CG, Bucci V, Stein RR, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2014;517:205-8.
14. Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407-15.
15. Tigchelaar EF, Zhernakova A, Dekens JA. Cohort profile: LifeLines DEEP, a prospective, general population cohort study in the northern Netherlands: study design and baseline characteristics. BMJ Open 2015;5:e006772.
16. Scholtens S, Smidt N, Swertz M a., et al. Cohort Profile: LifeLines, a three-generation cohort study and biobank. Int J Epidemiol 2015;44:1172-80.
17. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012;13:R79.
18. Caporaso JG, Kuczynski J, Stombaugh J, et al. correspondEnce QIIME allows analysis of high-throughput community sequencing data Intensity normalization improves color calling in SOLiD sequencing. Nat Publ Gr 2010;7:335-6.
19. Asnicar F, Weingart G, Tickle TL, et al. Compact graphical representation of phylogenetic data and metadata with GraPhlAn. PeerJ 2015;3:e1029.
20. Segata N, Haake S, Mannon P, et al. Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples. Genome Biol 2012;13:R42.
21. Amir I, Konikoff FM, Oppenheim M, et al. Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors. Environ Microbiol 2014;16:2905-14.
22. Zhang H, DiBaise JK, Zuccolo a, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA 2009;106:2365-70.
23. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile Infection in the United States. N Engl J Med 2015;372:825-34.
24. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014;370:1198-208.
25. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009;7:526-36.
26. Reeves AE, Theriot CM, Bergin IL, et al. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes 2011;2:145-58.
27. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197:435-8.
28. Antharam VC, Li EC, Ishmael A, et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol 2013;51:2884-92.
29. Rea MC, O'Sullivan O, Shanahan F, et al. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol 2012;50:867-75.
30. Baines SD, Crowther GS, Todhunter SL, et al F and MHW. Mixed infection by Clostridium difficile in an in vitro model of the human gut. J Antimicrob Chemother 2013;68:1139-43.
31. Schubert AM, Rogers M a M, Ring C, et al. Microbiome data distinguish patients with clostridium difficile infection and non-C. difficile-associated diarrhea from healthy. MBio 2014;5:e01021-14.
32. Peterfreund GL, Vandivier LE, Sinha R, et al. Succession in the Gut Microbiome following Antibiotic and Antibody Therapies for Clostridium difficile. PLoS ONE 2012;7.
33. Department H and HS. Request for Comments on the Proposed 2020 Targets for the National Action Plan To Prevent Health Care-Associated Infections: Road Map To Elimination (Phase I: Acute Care Hospital) Measures. 2014. https://www.federalregister.gov/articles/2014/02/25/2014-04069/request-for-comments-on-theproposed-2020-targets-for-the-national-action-plan-to-prevent-health
34. U. S. Food and Drug Administration. FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). 2012. http://www.fda.gov/drugs/drugsafety/ucm290510.htm
35. Blaser M. Antibiotic overuse: Stop the killing of beneficial bacteria. Nature 2011;476:393-4.
36. Mehal WZ. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat Rev Gastroenterol Hepatol 2013;10:637-44.
37. Goodrich JK, Waters JL, Poole AC, et al. Human Genetics Shape the Gut Microbiome. Cell 2014;159:789-99.